Ipamorelin
A selective growth hormone secretagogue (GHS) that stimulates GH release through the ghrelin receptor with minimal impact on cortisol and prolactin.
Mechanism of Action
Ipamorelin is a pentapeptide that selectively binds to GHS-R1a (ghrelin receptors) on anterior pituitary somatotrophs, triggering GH release. Unlike GHRP-6 and GHRP-2, ipamorelin does not significantly elevate cortisol, ACTH, prolactin, or aldosterone at therapeutic doses, making it the most selective GH secretagogue studied.
Key Published Studies
Ipamorelin, the First Selective Growth Hormone Secretagogue
Raun K, Hansen BS, Johansen NL, et al. — European Journal of Endocrinology (1998)
Ipamorelin demonstrated potent and dose-dependent GH release in rats and swine with no significant effect on ACTH, cortisol, prolactin, or FSH/LH levels.
The Effect of Ipamorelin on Body Composition and Bone Mineral Content in Aged Female Rats
Svensson J, Lall S, Dickson SL, et al. — Growth Hormone and IGF Research (2000)
Chronic ipamorelin administration increased lean body mass and bone mineral content in aged rats without significant changes in fat mass or blood glucose.
Dosage Range
Subcutaneous research doses: 100-300 mcg, 2-3 times daily. Often combined with CJC-1295 (no DAC).
Reconstitution
Reconstitute with bacteriostatic water. For a 5 mg vial, add 2.5 mL BAC water for a 2 mg/mL solution.
Storage
Store lyophilized at -20C. Reconstituted at 2-8C, use within 21 days.
Half-Life
Approximately 2 hours. GH elevation peaks at 30-40 minutes post-injection.
Related Products
For Research Use Only. The information on this page is intended for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. All products sold by PrestigePeptides are strictly for laboratory research use and are not intended for human or veterinary consumption.
Ready to start your research?